Patients with head and neck squamous cell carcinoma often develop secondary squamous lesions in the esophagus or lungs, and discerning whether such lesions represent metastases or independent second primary tumors remains a key diagnostic challenge. A new study published in Cellular Oncology reports that, in the majority of cases analyzed, these thoracic lesions are in fact metastases sharing a common clonal origin with the primary head and neck tumor. The distinction between a metastasis and a second primary tumor is a key diagnostic challenge in these patients, and the study's authors describe their work as initial genomic evidence supporting the molecular characterization of metastatic lesions and second primary tumors in head and neck-thoracic squamous carcinomas.
The research team, led by Meixuan Wan, Xinxin Yang and colleagues with senior author Hongxue Meng, analyzed 71 tumor samples drawn from 20 patients with multifocal squamous cell carcinomas. Using whole-exome sequencing, the investigators reconstructed the clonal relationships among tumors from the same patient to determine which lesions shared a common origin. They paired this genomic work with multiplex immunofluorescence to characterize immune heterogeneity.
The clonal reconstruction delivered the study’s central result: most thoracic secondary squamous lesions shared a common origin with the primary head and neck tumors, indicating metastatic dissemination rather than independent second primaries. This genomic evidence is described by the authors as initial support for the molecular characterization of metastatic lesions and second primary tumors in head and neck-thoracic squamous carcinomas, an area where diagnostic ambiguity has long persisted.
Beyond resolving the tumors’ ancestry, the study identified a molecular player in the spread itself. The protein FHL2, short for tetramer half-LIM domain protein 2, was found to be enriched in metastatic clones and flagged as a potential driver gene. Mechanistically, the researchers showed that FHL2 directly interacts with EGFR, a cell-surface receptor already central to head and neck cancer biology, and enhances its phosphorylation. That sustained EGFR activity keeps the PI3K-AKT signaling pathway running, which in turn promotes the cytoplasmic retention of FOXO3, a transcription factor with tumor-suppressive functions. Trapped in the cytoplasm, FOXO3 cannot activate its tumor-suppressive transcriptional program, and the result, according to the study, is accelerated tumor growth and dissemination.
To test whether this mechanism could be exploited therapeutically, the team turned to a lung metastasis model. When tumors overexpressing FHL2 were treated with cetuximab, an EGFR-targeted antibody, the metastatic burden was markedly reduced. Clinical sample analysis added an exploratory translational layer: higher FHL2 expression showed a potential association with response to cetuximab in the study’s own cohort. The authors frame FHL2 as an exploratory candidate biomarker associated with response to EGFR-targeted therapy rather than a validated predictor, noting that higher FHL2 expression showed a potential association with response to cetuximab in their cohort.
The immune profiling revealed a second dimension to metastatic progression. Metastatic lesions exhibited reduced infiltration by CD4-positive and CD8-positive T cells, the two principal arms of the adaptive immune response that recognize and kill tumor cells, together with altered spatial distributions of PD-L1, an immune checkpoint molecule, and CD138-positive cells. In addition, high FHL2 expression was associated with lower CD4-positive and CD8-positive T-cell infiltration, linking the same molecule that drives dissemination to a colder immune environment around the tumor.
The study’s design combined complementary in vitro and in vivo experiments with analyses of clinical specimens, allowing the investigators to move from patient tissue to mechanism and back again. Whole-exome sequencing provided the clonal maps, multiplex immunofluorescence provided the spatial immune context, and the experimental models tested whether manipulating the FHL2-EGFR axis changed metastatic behavior. The study combined whole-exome sequencing, multiplex immunofluorescence, and complementary in vitro and in vivo experiments with analyses of clinical specimens, though the cohort of 20 patients remains modest and the biomarker finding is exploratory.
For clinical practice, the study addresses the diagnostic challenge of discerning whether secondary squamous lesions in the esophagus or lungs represent metastases or independent second primary tumors. The study analyzed 20 patients with multifocal squamous cell carcinomas in whom this distinction was a key diagnostic challenge. In this study, clonal reconstruction revealed that most thoracic secondary squamous lesions shared a common origin with the primary head and neck tumors, indicating metastatic dissemination rather than independent second primaries. The authors describe these findings as initial genomic evidence supporting the molecular characterization of metastatic lesions and second primary tumors in head and neck-thoracic squamous carcinomas.
The study also examined the role of FHL2 in metastatic HNSCC and its impact on tumor progression. In a lung metastasis model, EGFR-targeted therapy with cetuximab markedly reduced metastatic burden in tumors overexpressing FHL2, and clinical sample analysis showed that higher FHL2 expression had a potential association with response to cetuximab in the study's cohort. The authors position the finding as an exploratory candidate biomarker associated with response, and the potential association observed in their cohort will need validation before it informs decisions. The authors describe the study as providing initial genomic evidence supporting the molecular characterization of metastatic lesions and second primary tumors in head and neck-thoracic squamous carcinomas, with FHL2 suggested as an exploratory candidate biomarker associated with response to EGFR-targeted therapy.
Subject of Research: Clonal origin analysis of secondary thoracic lesions in head and neck squamous cell carcinoma and the role of FHL2 in metastatic progression
Article Title: Clonal origin analysis of secondary lesions reveals metastatic predominance and a role for FHL2 in head and neck squamous cell carcinomas
Article References: Wan, M., Yang, X., Deng, S., Yang, S., Guo, C., Zhao, X., Ju, R., Kuang, H., Cheng, Y., Guo, Y., & Meng, H. (2026). Clonal origin analysis of secondary lesions reveals metastatic predominance and a role for FHL2 in head and neck squamous cell carcinomas. Cellular Oncology. https://doi.org/10.1007/s13402-026-01316-0
Image Credits: AI Generated
DOI: 10.1007/s13402-026-01316-0
Keywords: head and neck squamous cell carcinoma, metastasis, second primary tumors, whole-exome sequencing, FHL2, EGFR, cetuximab, PI3K-AKT signaling, FOXO3, multiplex immunofluorescence, tumor immune microenvironment, biomarker
News Source: Nathaniel Bowman. (November 6, 2026). Most Secondary Chest Tumors in Head and Neck Cancer Are Metastases, Study Finds. Scienmag.
